The surface polysaccharides of bacterial pathogens, which include capsular polysaccharides and lipopolysaccharides, serve as protective antigens. The immunologic properties of these bacterial polysaccharides, namely their age-related and T-cell independent immunogenicity, limit their use as vaccines. Covalently attachment to medically-useful proteins to form conjugates, both increases their immunogenicity and confers T-cell dependent properties to these polysaccharides. The capsular polysaccharides of Streptococcus pneumococcus type 6B, Staphylococcus aureus types 5 and 8, Group B streptococcus type 3 have been bound to several proteins and evaluated clinically. S. aureus type 5-rEPA was evaluated in end stage renal disease patients; type 5 antibodies of the three major Ig classes rose significantly though to a lesser degree than in healthy volunteers, no booster response to reinjection at 6 weeks was found. These antibodies had opsonophagocytic activities. Pn6B-TT was evaluated in patients with sickle cell disease, healthy infants at 3, 4 and 6 months of age or at 7 and 9 months of age. Type specific antibodies of the three Ig classes, with booster responses, were induced. The magnitude of these responses was lesser than of Hib- TT. GBSIII-TT was evaluated in females of child bearing age. IgG antitype III rose similarly to the response to the polysaccharide alone. Technical problems with this lot were identified. All conjugates were safe, with only minor local reaction. The LPS of shigellae was detoxified, their O-specific polysaccharides bound to bacterial toxoids and their immunogennicity in mice found to be satisfactory. In Phase 1 and Phase 2 studies, these conjugates of the O-specific polysaccharides were safe and immunogenic: LPS antibody levels elicited by the investigational conjugates were similar to those in recruits convalescent from shigellosis. In preliminary studies, a S. sonnei-rEPA conjugate protected against shigellosis caused by this pathogen. A more extensive study showed protection of 75%.

Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
1995
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Jin, Zhigang; Romero-Steiner, Sandra; Carlone, George M et al. (2007) Haemophilus influenzae type a infection and its prevention. Infect Immun 75:2650-4
Kubler-Kielb, Joanna; Liu, Teh-Yung; Mocca, Christopher et al. (2006) Additional conjugation methods and immunogenicity of Bacillus anthracis poly-gamma-D-glutamic acid-protein conjugates. Infect Immun 74:4744-9
Fekete, Aniko; Hoogerhout, Peter; Zomer, Gijsbert et al. (2006) Synthesis of octa- and dodecamers of D-ribitol-1-phosphate and their protein conjugates. Carbohydr Res 341:2037-48
Kubler-Kielb, Joanna; Pozsgay, Vince (2005) A new method for conjugation of carbohydrates to proteins using an aminooxy-thiol heterobifunctional linker. J Org Chem 70:6987-90
Claesson, Bo A; Trollfors, Birger; Lagergard, Teresa et al. (2005) Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccine. Pediatr Infect Dis J 24:463-4
Jin, Zhigang; Bohach, Gregory A; Shiloach, Joseph et al. (2005) Conjugates of group A and W135 capsular polysaccharides of neisseria meningitidis bound to recombinant Staphylococcus aureus enterotoxin C1: preparation, physicochemical characterization, and immunological properties in mice. Infect Immun 73:7887-93
Robbins, John B; Schneerson, Rachel; Trollfors, Birger et al. (2005) The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis 191:81-8
Robbins, John B; Schneerson, Rachel; Gotschlich, Emil C (2005) Surveillance for bacterial meningitis by means of polymerase chain reaction. Clin Infect Dis 40:26-7
Glatman-Freedman, Aharona; Casadevall, Arturo; Dai, Zongdong et al. (2004) Antigenic evidence of prevalence and diversity of Mycobacterium tuberculosis arabinomannan. J Clin Microbiol 42:3225-31
Robbins, John B; Schneerson, Rachel (2004) Future vaccine development at NICHD. Ann N Y Acad Sci 1038:49-59

Showing the most recent 10 out of 33 publications